1H26 Results Beat Expectations; AIDD Drives Growth and Target Price Upgrade
AI summary card
1H26 Results Beat Expectations; AIDD Drives Growth and Target Price Upgrade
JPMorgan maintains its Overweight rating on Genscript Biotech - H and raises its target price to HK$35, primarily driven by AIDD demand supporting LSG growth, margin improvement, and a full-year guidance upgrade.
- 1H26 revenue was US$404.2mn, up 27.3% year on year; adjusted net profit was US$62.5mn, up 203.3% year on year, both excluding the impact of LaNova.
- LSG revenue was US$319.0mn, up 28.8% year on year; adjusted operating profit doubled to US$94mn, with an adjusted operating margin of 29.5%.
- LSG FY26E revenue growth guidance was raised from 15%-18% to 25%-30%.
- AIDD revenue was close to US$40mn in 1H26, up more than 105% year on year; management expects 2H26 revenue to double and exceed US$100mn.
- The analyst raises FY26/27/28E sales forecasts by 1%/9%/17%, respectively, and increases FY26-FY28 adjusted net margin assumptions by 2-5 percentage points.
Report interpretation
Overview
Genscript Biotech - H is a biotechnology company covering life science CRO, biologics CDMO, and enzyme engineering businesses. JPMorgan believes the 1H26 earnings beat validates AIDD as a structural growth driver, with customer demand shifting from proof-of-concept toward frequent, large-scale wet-lab validation and model iteration.
Core views
AIDD demand, improvement in late-stage project business, and automated capacity expansion jointly support growth. Improved order mix and faster delivery capabilities at LSG are expected to drive margin expansion; despite relatively cautious management commentary, the report sees potential for a further guidance upgrade in 2H26.
Analysis framework
The report assesses the company using 1H26 results, management guidance, AIDD order and capacity information, peer operating comparisons, and DCF valuation, while extending the forecast period from 2033 to 2035.
Methodology notes
Discounted Free Cash Flow Valuation
Values free cash flow forecast through 2035 using an 11.0% WACC and a 3% terminal growth rate, deriving a December 2027 target price of HK$35.
Comparison with TWST US
The report notes that the company trades at approximately 8x 12-month forward P/S, below approximately 15x for TWST US, indicating further valuation upside.
Asset mapping & comparison
Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).
- Genscript Biotech - H（1548.HK）Covered Company
- Strengths
- Rapid AIDD demand growth, improving LSG profitability, better-than-expected late-stage project business, automated capacity expansion, and ample cash supporting capital expenditure.
- Weaknesses
- BestZyme FY26E revenue growth guidance was reduced from 10%-15% to 8%-10%; business growth still needs to be consistently delivered.
- Comparison
- The report believes the company provides end-to-end platform capabilities from sequence to validation data; versus TWST US, it has advantages in delivery speed, data turnaround, and revenue per unit of output, while trading at a lower forward P/S valuation.
- Risks
- Geopolitical risks, clinical failure of pipeline drug candidates, and regulatory risks.
- Legend Biotech（LEGN）Investee Company
- Strengths
- The company holds an approximately 45% equity interest.
- Weaknesses
- It is no longer consolidated, and is accounted for using the equity method.
- Comparison
- Not a core operating growth driver in this report.
- Risks
- Equity-method investment performance may affect volatility in the company's profits.
Key data
- 1H26 RevenueUS$404.2mn, up 27.3% year on yearOn a basis excluding the impact of LaNova.
- 1H26 Adjusted Net ProfitUS$62.5mn, up 203.3% year on yearExcluding the impact of LaNova.
- LSG 1H26 RevenueUS$319.0mn, up 28.8% year on yearAdjusted operating profit was US$94mn, with a margin of 29.5%.
- AIDD 1H26 RevenueClose to US$40mn, up more than 105% year on yearManagement expects this to double and exceed US$100mn in 2H26.
- LSG FY26E Revenue Growth Guidance25%-30%Previous guidance was 15%-18%.
- FY26E Capital Expenditure GuidanceApproximately US$130mnFor automation, technology platforms, and capacity expansion.
- Target PriceHK$35.00Based on DCF; the previous target price was HK$23.00.
Impact & implications
If AIDD customers continue increasing the frequency of validation and iteration, LSG could transition from one-off project demand to more recurring, high-value revenue. Expansion of automation and modular workstations should help alleviate capacity constraints, while improvement in late-stage project business could reduce reliance on a single growth driver.
Risks
- Geopolitical risks could affect cross-border operations, customer demand, or supply chains.
- Clinical failure of customers' pipeline drug candidates could weaken related validation and CDMO demand.
- Changes in the regulatory environment could affect business operations and commercialization timing.
- Lower-than-expected AIDD demand growth, order conversion, or capacity expansion could pressure revenue and margins.
- Disclosure matters, including investment banking and client relationships, may present conflict-of-interest considerations.
What to watch
- Whether 2H26 AIDD revenue can double and exceed US$100mn as management expects.
- Whether full-year LSG revenue growth can meet the upgraded 25%-30% guidance.
- The sustainability of new late-stage project orders and revenue and order growth in the China market.
- Progress of automation investment and capacity expansion, as well as execution of approximately US$130mn in FY26E capital expenditure.
- Whether margin improvement materializes, particularly through the contribution of high-value AIDD orders to the LSG mix.
- Whether slowing BestZyme growth further affects overall business performance.